- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/73 - Unsubstituted amino or imino radicals
Patent holdings for IPC class C07D 213/73
Total number of patents in this class: 592
10-year publication summary
|
34
|
45
|
48
|
54
|
36
|
40
|
38
|
40
|
44
|
22
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4757 |
14 |
| Vertex Pharmaceuticals Incorporated | 1577 |
14 |
| Qingdao Kingagroot Chemical Compound Co., Ltd. | 239 |
11 |
| Novartis AG | 10169 |
10 |
| Northwestern University | 3570 |
10 |
| Amgen Inc. | 4467 |
9 |
| Centre National de La Recherche Scientifique | 11111 |
8 |
| Board of Regents, The University of Texas System | 6172 |
8 |
| Merck Patent GmbH | 5747 |
7 |
| Bayer Pharma AG | 1005 |
7 |
| BASF SE | 21320 |
6 |
| Bayer Cropscience AG | 1830 |
6 |
| FUJIFILM Corporation | 30689 |
6 |
| Arcus Biosciences, Inc. | 166 |
6 |
| Celgene Quanticel Research, Inc. | 154 |
6 |
| Intervet International B.V. | 1337 |
6 |
| Oryzon Genomics S.A. | 103 |
6 |
| Merck Sharp & Dohme LLC | 3733 |
6 |
| F. Hoffmann-La Roche AG | 7798 |
5 |
| E. I. du Pont de Nemours and Company | 3460 |
5 |
| Other owners | 436 |